http://bio2rdf.org/drugbank_resource:DB00872_DB04835_nanopub.RA1WlSHtlImzM47x3HPUGcMgRdLPzK6GAnuUYONrXDLdQ#head http://bio2rdf.org/drugbank_resource:DB00872_DB04835_nanopub.RA1WlSHtlImzM47x3HPUGcMgRdLPzK6GAnuUYONrXDLdQ http://www.nanopub.org/nschema#hasAssertion http://bio2rdf.org/drugbank_resource:DB00872_DB04835_nanopub.RA1WlSHtlImzM47x3HPUGcMgRdLPzK6GAnuUYONrXDLdQ#assertion http://bio2rdf.org/drugbank_resource:DB00872_DB04835_nanopub.RA1WlSHtlImzM47x3HPUGcMgRdLPzK6GAnuUYONrXDLdQ http://www.nanopub.org/nschema#hasProvenance http://bio2rdf.org/drugbank_resource:DB00872_DB04835_nanopub.RA1WlSHtlImzM47x3HPUGcMgRdLPzK6GAnuUYONrXDLdQ#provenance http://bio2rdf.org/drugbank_resource:DB00872_DB04835_nanopub.RA1WlSHtlImzM47x3HPUGcMgRdLPzK6GAnuUYONrXDLdQ http://www.nanopub.org/nschema#hasPublicationInfo http://bio2rdf.org/drugbank_resource:DB00872_DB04835_nanopub.RA1WlSHtlImzM47x3HPUGcMgRdLPzK6GAnuUYONrXDLdQ#publicationInfo http://bio2rdf.org/drugbank_resource:DB00872_DB04835_nanopub.RA1WlSHtlImzM47x3HPUGcMgRdLPzK6GAnuUYONrXDLdQ http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://bio2rdf.org/drugbank_resource:DB00872_DB04835_nanopub.RA1WlSHtlImzM47x3HPUGcMgRdLPzK6GAnuUYONrXDLdQ#assertion http://bio2rdf.org/drugbank:DB00872 http://bio2rdf.org/drugbank_vocabulary:ddi-interactor-in http://bio2rdf.org/drugbank_resource:DB00872_DB04835 http://bio2rdf.org/drugbank:DB04835 http://bio2rdf.org/drugbank_vocabulary:ddi-interactor-in http://bio2rdf.org/drugbank_resource:DB00872_DB04835 http://bio2rdf.org/drugbank_resource:DB00872_DB04835 http://purl.org/dc/terms/identifier drugbank_resource:DB00872_DB04835 http://bio2rdf.org/drugbank_resource:DB00872_DB04835 http://purl.org/dc/terms/title DDI between Conivaptan and Maraviroc - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc. When used with a strong CYP3A4 inhibitor, the adult dose of maraviroc should be decreased to 150 mg twice daily. Maraviroc is contraindicated in patients with severe renal impairment (creatinine clearance less than 30 mL/min) receiving a strong CYP3A4 inhibitor. Maraviroc may be administered at a dose of 300 mg twice daily with concomitant tipranavir/ritonavir but not with other ritonavir combinations. http://bio2rdf.org/drugbank_resource:DB00872_DB04835 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://bio2rdf.org/drugbank_vocabulary:Drug-Drug-Interaction http://bio2rdf.org/drugbank_resource:DB00872_DB04835 http://www.w3.org/2000/01/rdf-schema#label DDI between Conivaptan and Maraviroc - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc. When used with a strong CYP3A4 inhibitor, the adult dose of maraviroc should be decreased to 150 mg twice daily. Maraviroc is contraindicated in patients with severe renal impairment (creatinine clearance less than 30 mL/min) receiving a strong CYP3A4 inhibitor. Maraviroc may be administered at a dose of 300 mg twice daily with concomitant tipranavir/ritonavir but not with other ritonavir combinations. [drugbank_resource:DB00872_DB04835] http://bio2rdf.org/drugbank_resource:DB00872_DB04835_nanopub.RA1WlSHtlImzM47x3HPUGcMgRdLPzK6GAnuUYONrXDLdQ#provenance http://bio2rdf.org/drugbank_resource:DB00872_DB04835_nanopub.RA1WlSHtlImzM47x3HPUGcMgRdLPzK6GAnuUYONrXDLdQ#assertion http://semanticscience.org/resource/SIO_000253 http://bio2rdf.org/drugbank_resource:bio2rdf.dataset.drugbank.R3 http://bio2rdf.org/drugbank_resource:DB00872_DB04835_nanopub.RA1WlSHtlImzM47x3HPUGcMgRdLPzK6GAnuUYONrXDLdQ#publicationInfo http://bio2rdf.org/drugbank_resource:DB00872_DB04835_nanopub.RA1WlSHtlImzM47x3HPUGcMgRdLPzK6GAnuUYONrXDLdQ#signature.MCwCFGcXff2vJ0Ph http://purl.org/nanopub/x/hasPublicKey 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 http://bio2rdf.org/drugbank_resource:DB00872_DB04835_nanopub.RA1WlSHtlImzM47x3HPUGcMgRdLPzK6GAnuUYONrXDLdQ#signature.MCwCFGcXff2vJ0Ph http://purl.org/nanopub/x/hasSignature MCwCFGcXff2vJ0PhzF5uu8x0HHGqoee4AhRoqq8NUTHd3ee1L4EoB5UamNphEA== http://bio2rdf.org/drugbank_resource:DB00872_DB04835_nanopub.RA1WlSHtlImzM47x3HPUGcMgRdLPzK6GAnuUYONrXDLdQ#signature.MCwCFGcXff2vJ0Ph http://purl.org/nanopub/x/signedBy https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB http://bio2rdf.org/drugbank_resource:DB00872_DB04835_nanopub.RA1WlSHtlImzM47x3HPUGcMgRdLPzK6GAnuUYONrXDLdQ http://purl.org/dc/terms/created 2018-03-30T11:13:01.809+02:00 http://bio2rdf.org/drugbank_resource:DB00872_DB04835_nanopub.RA1WlSHtlImzM47x3HPUGcMgRdLPzK6GAnuUYONrXDLdQ http://purl.org/dc/terms/license https://creativecommons.org/licenses/by-nc/4.0/ http://bio2rdf.org/drugbank_resource:DB00872_DB04835_nanopub.RA1WlSHtlImzM47x3HPUGcMgRdLPzK6GAnuUYONrXDLdQ http://purl.org/nanopub/x/hasSignatureElement http://bio2rdf.org/drugbank_resource:DB00872_DB04835_nanopub.RA1WlSHtlImzM47x3HPUGcMgRdLPzK6GAnuUYONrXDLdQ#signature.MCwCFGcXff2vJ0Ph http://bio2rdf.org/drugbank_resource:DB00872_DB04835_nanopub.RA1WlSHtlImzM47x3HPUGcMgRdLPzK6GAnuUYONrXDLdQ http://www.w3.org/ns/prov#wasGeneratedBy https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11 https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB http://www.w3.org/ns/prov#specializationOf https://github.com/tkuhn/bio2rdf2nanopub https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB http://www.w3.org/ns/prov#wasAttributedTo http://orcid.org/0000-0002-1267-0234 https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11 http://purl.org/dc/terms/identifier 3c184e6c-ceb8-4275-a679-71dfbdac2a11 https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11 http://www.w3.org/ns/prov#used https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349 https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11 http://www.w3.org/ns/prov#wasAssociatedWith https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11 http://www.w3.org/ns/prov#wasStartedBy http://orcid.org/0000-0002-1267-0234 https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349 http://purl.org/dc/terms/isVersionOf https://github.com/tkuhn/bio2rdf2nanopub https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349 http://purl.org/pav/version eda7951a5f6c622c5d2132f50c3093138484a349 https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349 http://www.w3.org/ns/prov#wasAttributedTo http://orcid.org/0000-0002-1267-0234